Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. (NASDAQ: MYNZ) is a molecular genetics diagnostic company focused on the early detection of cancer, and its news flow reflects both scientific progress and commercial execution. Company updates frequently highlight developments around its flagship colorectal cancer screening test, ColoAlert, and its pancreatic cancer screening program, including PancAlert and related biomarker studies.
Investors and observers following MYNZ news can expect announcements on regulatory milestones, such as registrations and approvals that enable ColoAlert to be marketed in additional countries, as well as commercial partnerships with diagnostic laboratories, distributors, and digital health platforms. Examples include agreements to launch ColoAlert in Switzerland through a local laboratory partner, collaborations to introduce the test in South America, and inclusion of ColoAlert in digital preventive healthcare offerings in Germany.
News items also cover Mainz Biomed’s clinical development activities. These include updates on the eAArly DETECT and eAArly DETECT 2 studies for next generation colorectal cancer testing, presentations of clinical data on RNA‑based screening at international meetings, and feasibility and verification studies for blood‑based pancreatic cancer screening using licensed mRNA biomarkers and AI‑assisted algorithms. The company regularly announces participation in major conferences such as the American Association for Cancer Research Annual Meeting, MEDICA, and colorectal cancer screening committees organized by professional societies.
In addition, MYNZ news may include capital markets disclosures, such as securities purchase agreements, equity distribution arrangements, and summaries of financial reports filed on Form 6‑K. For readers seeking a consolidated view of these developments, this page provides a chronological feed of press releases and regulatory news that illustrate how Mainz Biomed is advancing its molecular diagnostic products, expanding market access, and managing its financing activities. Regular visits can help track scientific milestones, geographic expansion of ColoAlert, and progress in the company’s pancreatic cancer program.
Mainz Biomed (NASDAQ:MYNZ) announced plans to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025, with top-line results expected in Q4 2025. The study evaluates the company's next-generation colorectal cancer (CRC) screening test across approximately 2,000 average-risk patients.
The test combines proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test to detect both cancerous polyps and precancerous adenomas. Based on the study's outcome, Mainz Biomed plans to finalize protocols for ReconAAsense, its U.S. pivotal study, scheduled to begin in 2026.
The company's five novel gene expression biomarkers, acquired from Sherbrooke University in 2022, have shown capability in identifying advanced adenomas and early-stage CRC, potentially advancing CRC screening to prevention.
Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, has formed a strategic technology partnership with EDX Medical Group (AQSE: EDX). This collaboration will enable EDX Medical to leverage Mainz Biomed's molecular diagnostic technology for expanding its product portfolio in the UK market.
The partnership combines Mainz Biomed's expertise in molecular diagnostics with EDX Medical's capabilities in developing digital diagnostic products for cancer, cardiovascular, and infectious diseases. EDX Medical, based in the UK, specializes in creating diagnostic solutions that support personalized treatments.
Key highlights of the partnership:
- Focus on improving access to high-quality cancer diagnostics in the UK
- Integration of molecular biomarkers for enhanced early cancer detection
- Expansion of EDX Medical's diagnostic product portfolio
Mainz Biomed (NASDAQ: MYNZ) has provided its Q1 2025 corporate update, highlighting significant progress in its colorectal cancer (CRC) screening initiatives. The company enrolled its first patient in the eAArly DETECT 2 feasibility study, which will evaluate their next-generation CRC test incorporating mRNA biomarkers, AI algorithms, and FIT testing across 2,000 average-risk patients.
Key developments include a license agreement with Liquid Biosciences for pancreatic cancer biomarkers showing 95% sensitivity and 98% specificity, and a strategic partnership with labor team w ag to introduce ColoAlert® in Switzerland. Additionally, GANZIMMUN Diagnostics launched an enhanced version of ColoAlert across Germany in January 2025.
The company has regained full compliance with Nasdaq listing requirements, including minimum stockholders' equity and bid price requirements.
Mainz Biomed (NASDAQ:MYNZ) reported its 2024 financial results, highlighting a 33% year-over-year increase in lab network revenue for ColoAlert® in Europe. The company achieved significant cost reductions, resulting in a 30% decrease in operating loss and an 18% reduction in net loss.
Key developments include strategic partnerships with Thermo Fisher Scientific for next-generation colorectal cancer screening product development and Quest Diagnostics for clinical trial services. The company completed an $8.0 Million follow-on offering and focused on three core initiatives: European ColoAlert® business growth, next-generation product development, and the 2,000-patient eAArly DETECT 2 study.
Financial highlights for 2024 include:
- Revenue: $893,991
- Gross profit: $574,883 (64% margin)
- Net loss: $21.65 million
- Cash position: $6.24 million as of December 31, 2024
Mainz Biomed (NASDAQ:MYNZ) has enrolled its first patient in the eAArly DETECT 2 clinical study, a significant milestone in evaluating their next-generation colorectal cancer (CRC) test. The study will assess approximately 2,000 average-risk patients and combines proprietary mRNA biomarkers, an AI-developed algorithm, and a FIT test.
The study aims to validate previous feasibility results and support the transition from CRC screening to prevention. Enrollment is expected to complete in H2 2025, with top-line results targeted for Q4 2025. The outcome will help finalize protocols for ReconAAsense, the company's U.S. pivotal study planned for 2026.
The test incorporates five novel gene expression biomarkers acquired from Sherbrooke University in 2022, which have shown ability to identify both advanced adenomas (precancerous colonic polyps) and early-stage CRC. The study seeks to enhance diagnostic sensitivity and specificity for early-stage CRC detection.
Mainz Biomed (NASDAQ:MYNZ) has entered into a License and Option Agreement with Liquid Biosciences for novel mRNA biomarkers enabling non-invasive pancreatic cancer detection via blood tests. The groundbreaking discovery analysis demonstrated 95% sensitivity and 98% specificity in detecting pancreatic cancer.
The study involved multiple independent cohorts, with initial discovery using a blood-based cohort of 285 subjects, including 35 pancreatic cancer patients. The agreement grants Mainz exclusive license rights and an option to acquire global rights to the gene expression biomarkers, involving both a license fee and future revenue royalties.
The companies will jointly develop the pancreatic cancer screening test, focusing on commercial assay enhancement, algorithm refinement, and FDA application preparation. If statistical results prove replicable in a new product, this could position Mainz's test as the market's most robust pancreatic cancer screening solution.
Mainz Biomed (NASDAQ:MYNZ) is marking Colorectal Cancer Awareness Month with a focus on transforming screening into prevention. The company highlights that colorectal cancer (CRC) remains the second leading cause of cancer deaths globally, causing over 930,000 deaths annually, with 150,000 diagnoses in the U.S. and 22,836 deaths in Germany.
The company's research has yielded promising results through their ColoFuture and eAArly DETECT studies, achieving 82% sensitivity in advanced adenoma detection with 97% specificity using mRNA biomarkers, FIT test, and AI algorithms. Their flagship product, ColoAlert®, is expanding through laboratory partnerships, including a recent collaboration in Switzerland.
To increase accessibility, Mainz Biomed has implemented at-home testing solutions through European Oncology Lab's web platform. The company emphasizes that while CRC is highly preventable, low screening participation continues to make it a leading cause of cancer deaths, driving their mission to enhance early detection and prevention strategies.
Mainz Biomed (NASDAQ:MYNZ) has announced a strategic partnership with labor team w ag to launch ColoAlert®, a DNA-based colorectal cancer (CRC) screening test, in Switzerland. This marks Mainz Biomed's first entry into the Swiss market, where thousands of new CRC cases are diagnosed annually.
The partnership combines Mainz Biomed's DNA-based diagnostic expertise with labor team w's established laboratory services network. The ColoAlert® test will be available through labor team w's healthcare provider network starting in spring 2025, offering Swiss patients access to advanced CRC screening technology.
This collaboration aims to increase CRC screening participation rates and improve early detection capabilities in Switzerland. The partnership represents an expansion of Mainz Biomed's European market presence with its flagship product ColoAlert®, which is the first DNA-based CRC screening test in Europe.
Mainz Biomed (NASDAQ:MYNZ) and GANZIMMUN Diagnostics have launched an enhanced version of the ColoAlert colorectal cancer screening test across Germany, timing the release with March's Colorectal Cancer Awareness Month. The improved test, first introduced in mid-2024, features a proprietary DNA stabilizing buffer that ensures accurate results regardless of sample volume variations.
The launch coincides with Germany's updated national screening guidelines, which now provide equal access to colorectal cancer screening for both men and women starting at age 50, eliminating previous gender-based differences. This change follows research by the Institute for Quality and Efficiency in Health Care (IQWiG) that found no significant gender-based variations in recommended screening methods.
According to Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed, this development advances their mission of improving colorectal cancer prevention and detection. The collaborative effort between Mainz Biomed and GANZIMMUN demonstrates their commitment to enhancing cancer diagnostics through innovative solutions.